MedTrace Logo

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

NCT02734849 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

This is a phase 2 study to evaluate multiple doses of AK001 across 2 active doses. Pharmacodynamic activity will also be evaluated.

Conditions

  • Nasal Polyposis

Interventions

DRUG

AK001 low dose

25 mg AK001 will be administered as multiple doses

DRUG

AK001 high dose

250 mg AK001 will be administered as multiple doses

DRUG

Placebo

Placebo will be administered as multiple doses

Sponsors & Collaborators

  • Allakos Inc.

    lead INDUSTRY

Principal Investigators

  • Claus Bachert · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States
  • Belgium
  • Germany
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02734849 on ClinicalTrials.gov